Latest From Pfenex Inc.
Daiichi Sankyo obtains rights to antiemetic Nasea and the anti-hypertension drugs Perdipine and Oldeca. Mitsubishi Tanabe licenses Asian rights to Viela’s inebilizumab for a rare eye disorder.
Alvogen has signed marketing deals with local firms in Canada, Israel and South Korea for the teriparatide drug it has licensed from Pfenex. In the US, Pfenex has just completed a human factors study it feels should support a therapeutic equivalence rating for its Forteo rival.
The latest drug development news and highlights from our US FDA Performance Tracker.
Pfenex’ PF708 version of Forteo, submitted under the US 505(b)(2) hybrid regulatory pathway, has been approved by the FDA. Marketing partner Alvogen is expected to launch as soon as the FDA decides on the product’s equivalence rating after Pfenex submits a key study.
- Drug Discovery Tools
- Large Molecule
- Synthesis Technologies, Production Processes
- Generic Drugs
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Pfenex Inc.
- Senior Management
Evert (Eef) Schimmelpennink, Pres. & CEO
Susan Knudson, CFO
Patrick K Lucy, CBO
Hubert C Chen, MD, CMO & CSO
- Contact Info
Phone: (858) 352-4400
10790 Roselle St.
San Diego, CA 92121
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.